Key result
Prenatal antiarrhythmics reduce fetal heart rate ~51% in a fetus with SVT and hydrops fetalis.
Why the study?
Fetal supraventricular tachycardia can lead to congestive cardiac failure and non-immune fetal hydrops, requiring accurate prenatal diagnosis and management to improve outcomes.
Does prenatal antiarrhythmic therapy or early delivery improve outcomes in fetuses with supraventricular tachycardia?
Population
2 pregnant women with fetuses diagnosed with SVT including one with hydrops fetalis and one with Ebstein anomaly
Comparison
Maternal antiarrhythmic drug therapy and direct fetal drug administration versus elective delivery
Design
Case report
Authors
Loading...
May support prenatal antiarrhythmic consideration in hydropic fetal SVT; hypothesis-generating and should not yet change practice.
Case Report (n=2)
No
Does prenatal antiarrhythmic therapy or early delivery improve outcomes in fetuses with supraventricular tachycardia?
Early identification and intervention of fetal supraventricular tachycardia, particularly before the development of hydrops fetalis, is crucial for improving perinatal outcomes.
Rasanjana et al. (2015) conducted a case report in Fetal supraventricular tachycardia (n=2). Antiarrhythmic drugs (digoxin, sotalol, flecainide, amiodarone) and elective delivery was evaluated on Fetal heart rate reduction. Prenatal administration of antiarrhythmic drugs successfully reduced fetal heart rate from 278 bpm to 137 bpm in a fetus with supraventricular tachycardia and hydrops fetalis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: